Loading...
XNASVIRX
Market cap9mUSD
Dec 26, Last price  
0.24USD
1D
-5.20%
1Q
6.76%
Jan 2017
-93.45%
IPO
-99.37%
Name

Viracta Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:VIRX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
106.99%
Rev. gr., 5y
-7.52%
Revenues
0k
16,521,85013,709,1869,663,5135,417,3403,761,54733,0835,000,0003,754,0007,956,0005,734,0003,061,0002,536,000669,000237,0002,073,000120,000000
Net income
-51m
L+2.58%
-27,488,933-31,230,388-40,317,086-37,356,935-63,238,979-24,587,485-20,441,000-45,806,000-37,515,000-44,721,000-36,676,000-38,023,000-35,458,000-26,615,000-23,330,000-19,199,000-203,062,000-49,774,000-51,058,000
CFO
-40m
L+12.51%
-20,945,737-27,084,635-34,455,646-35,460,959-20,183,029-19,379,421-22,836,000-10,642,000-37,423,000-43,181,000-38,731,000-36,962,000-36,142,000-24,404,000-22,185,000-16,054,000-18,851,000-35,457,000-39,892,000
Earnings
Mar 05, 2025

Profile

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
URL
https://www.viracta.com/
IPO date
Sep 27, 2005
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
51,185
50,799
39,476
Unusual Expense (Income)
NOPBT
(51,185)
(50,799)
(39,476)
NOPBT Margin
Operating Taxes
577
88,300
Tax Rate
NOPAT
(51,185)
(51,376)
(127,776)
Net income
(51,058)
2.58%
(49,774)
-75.49%
(203,062)
957.67%
Dividends
Dividend yield
Proceeds from repurchase of equity
299
2,331
62,320
BB yield
-1.36%
-4.22%
-53.57%
Debt
Debt current
25,838
278
381
Long-term debt
282
25,155
5,756
Deferred revenue
Other long-term liabilities
Net debt
(27,571)
(65,610)
(97,417)
Cash flow
Cash from operating activities
(39,892)
(35,457)
(18,851)
CAPEX
(138)
(45)
(4,252)
Cash from investing activities
14,998
(53,866)
12,891
Cash from financing activities
438
22,542
62,425
FCF
(51,235)
(50,908)
(127,628)
Balance
Cash
53,691
91,043
103,554
Long term investments
Excess cash
53,691
91,043
103,554
Stockholders' equity
(260,467)
(209,596)
(160,221)
Invested Capital
304,624
295,854
260,070
ROIC
ROCE
EV
Common stock shares outstanding
38,624
37,791
31,870
Price
0.57
-60.96%
1.46
-60.00%
3.65
-47.63%
Market cap
22,016
-60.10%
55,175
-52.57%
116,326
17,888.43%
EV
(103)
(4,983)
24,361
EBITDA
(50,693)
(50,589)
(39,298)
EV/EBITDA
0.00
0.10
Interest
3,704
577
491
Interest/NOPBT